Rapid growth in emerging markets, significant new market players and unprecedented levels of M&A are generating both challenges and opportunities for chemicals companies and those investing in the sector.

At Linklaters, we understand and can support our clients in addressing some of the key issues including:
  • fast changing competitive landscape with the recent M&A spike and the break-up of the traditional chemicals conglomerate
  • shift in global sector economics with the supply base moving west and the demand base moving east
  • extraterritorial reach of national laws which have far reaching implications for global businesses

We advise chemicals companies and those investing in the sector on a wide range of corporate, M&A and finance matters and we have a strong regulatory team who are extremely well placed to advise on sector-specific issues such as product and trade regulations.

Through our long history of advising clients in the chemicals sector and our recent roles on three of the four ‘mega-mergers’ we understand how the chemicals sector works and what drives the companies operating and investing in this space. This means that we do not need to spend time getting to grips with the basic issues and are able to provide you with informed, targeted and commercial advice from the outset, saving you time and money.

Recent experience includes advising:
  • BP on the $5bn sale of its Acetyls and Aromatics businesses to INEOS, the global manufacturer of petrochemicals, speciality chemicals and oil products
  • Linde on its US$5bn establishment of a new Multi-Issuer Commercial Paper Programme
  • BASF SE on the €3.1bn sale of its construction chemicals business to private equity firm Lone Star
  • The export credit agencies and other financial institutions on the $14bn SATORP Jubail refining and petrochemical plant in Saudi Arabia
  • Merck on its new €2bn syndicated multicurrency revolving credit facility agreement
  • Bayer on the US$57bn financing to support its proposed acquisition of agrochemical company Monsanto
  • HSBC and other lenders on the debt financing for ChemChina on the US$43bn acquisition of Syngenta
  • Solvay on the US$5.5bn merger agreement with Cytec and on the subsequent reorganisation of its corporate structure